IP Library Patent Application 16837858
Patent Application
App. No. 16/837,858

COMPOSITIONS AND METHODS AGAINST P. AERUGINOSA INFECTIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/837,858
Abstract

A combination of an antibody and other therapeutic that work together in vivo against a pathogenic microbe. The combination can include the antibody with an antibiotic, and/or a therapeutic against a disease. The combination can attack the pathogenic microbe with an efficiency more than either of the components alone, with a synergistic effect, or an effect moderated by one or more modes of action not existing with administration of either the antibody or therapeutic alone.

Claims (9)

1 . A composition comprising:

an isolated polypeptide that selectively binds to P. aeruginosa mucoid exopolysaccharide; and,

an antibiotic selected from the group consisting of: a carbapenem, a polymyxin a carboxypenicillin, a fluoroquinolone, and an aminoglycoside;

wherein the combination of the polypeptide and antibiotic provides a bactericidal effect greater than either alone.

2 . The composition of claim 1 , wherein the combination of the polypeptide and antibiotic provides an additive bactericidal effect.

3 . The composition of claim 1 , wherein the combination of the polypeptide and antibiotic provides a synergistic effect greater an additive bactericidal effect.

4 . The composition of claim 1 , wherein the combination of the polypeptide and antibiotic provides the same or less than an additive effect, but the overall effect is enhanced by one or more interactions between the antibody and antibiotic, which enhancement is driven by a mode of action not present with either the antibody or antibiotic alone.

5 . The composition of claim 1 , wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 5 and SEQ ID NO: 7 or a variant having at least 95% identity to SEQ ID NO: 5 or SEQ ID NO: 7.

6 - 32 . (canceled)

Assignments (2)
SECURITY INTEREST Recorded Jun 21, 2023
From: ARIDIS PHARMACEUTICALS, INC.; ARIDIS BIOPHARMACEUTICALS, LLC; ARIDIS PHARMACEUTICALS, C.V.
To: STREETERVILLE CAPITAL, LLC
Reel/Frame 064020/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 3, 2020
From: TRUONG-LE, VU
To: ARIDIS PHARMACEUTICALS, INC.
Reel/Frame 053689/0015 →